Antibody therapy against antibiotic-resistant diarrheagenic Escherichia coli: a systematic review

Immunotherapy. 2021 Oct;13(15):1305-1320. doi: 10.2217/imt-2021-0079. Epub 2021 Aug 31.

Abstract

Over four billion episodes of diarrhea occur annually in developing countries with diarrheagenic Escherichia coli (DEC) outbreaks also being reported, until now bacterial diarrhea is conventionally addressed by the antibiotic treatment regimes. In recent decades, the emergence of antimicrobial-resistant strains has become a major obstacle in diarrheal treatment; hence, novel and ideal therapeutics are needed. Notably, 80% of DEC is resistant to first-class antibiotics. Among the existing strategies, passive immunization is considered as an alternative to combat drug-resistant bacteria. Antibodies specific to an antigen can be used for prophylactic and therapeutic purposes. In this review, we have systematically discussed the effect of passive immunotherapy to combat DEC and explored the types and advancements in antibodies used against antibiotic-resistant DEC.

Keywords: E. coli; antibiotic resistance; antibody therapy; chicken IgY; diarrhea; monoclonal antibody; passive immunization; polyclonal antibody; recombinant antibody; therapeutic antibodies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Systematic Review

MeSH terms

  • Diarrhea / drug therapy*
  • Diarrhea / immunology*
  • Drug Resistance, Bacterial / drug effects*
  • Escherichia coli / drug effects*
  • Escherichia coli / immunology*
  • Humans
  • Immunotherapy / methods*